GC 001
Alternative Names: GC-001Latest Information Update: 03 Nov 2024
Price :
$50 *
At a glance
- Originator Hangzhou Gongchu Biotechnology
- Class Antineoplastics; Immunotherapies; Oncolytic viruses
- Mechanism of Action Cell death stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Glioma; Solid tumours
Most Recent Events
- 08 Oct 2024 Phase-I clinical trials in Glioma (Late-stage disease, Second-line therapy or greater) in China (Intratumoural) (NCT06660056)
- 26 Apr 2023 Phase-I clinical trials in Solid tumours (Late-stage diseases) in China (Intratumoural) (NCT06508307)